<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35253622</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>211</StartPage>
          <EndPage>224</EndPage>
          <MedlinePgn>211-224</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2046450</ELocationID>
        <Abstract>
          <AbstractText>Endometrial cancer (EC) is a gynecological malignant tumor characterized by high incidence. EC occurrence and development are regulated by numerous molecules and signal pathways. There is a need to explore key regulatory molecules to identify potential therapeutic targets to reduce the incidence of EC. Treatment by targeting a single molecule is characterized by poor efficacy owing to the development of resistance and significant side effects. The current study explored potential candidates in EC by integrating bioinformatics analysis and in vivo and in vitro experimental validation to circumvent the limitation of low efficacy of currently used molecules. Molecular dynamics simulations provide details at the molecular level of intermolecular regulation. In the current study, MLLT11 and TRIL were identified as important regulatory molecules in EC. The two molecules formed a heteromultimer by binding to AKT protein, which induced its phosphorylation of threonine at position 308. Ultimately, the complex stimulates PI3K/AKT/mTOR signaling pathway, a pivotal pathway in tumors. The findings of the current study show a novel complex, MLLT11-TRIL, which can act as AKT protein agonist, thus inducing activity of PI3K/AKT/mTOR signaling pathway. Targeting MLLT11 and TRIL simultaneously, or blocking the formation of the MLLT11-TRIL complex, can abrogate progression of EC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Jingnan</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-0392-6517</Identifier>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-3910-3712</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Mingming</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0186-2721</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jinjin</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-5655-8888</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mingyuan</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-4867-0508</Identifier>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Geratic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C091736">MLLT11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="Y">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="Y">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AKT</Keyword>
        <Keyword MajorTopicYN="Y">Endometrial cancer (EC)</Keyword>
        <Keyword MajorTopicYN="Y">MLLT11</Keyword>
        <Keyword MajorTopicYN="Y">PI3K/AKT/mTOR signaling pathway</Keyword>
        <Keyword MajorTopicYN="Y">TRIL</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>8</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35253622</ArticleId>
        <ArticleId IdType="pmc">PMC8903758</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2022.2046450</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017;13(3):608–624. doi:10.1080/15548627.2016.1271512. PMID:28055301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1271512</ArticleId>
            <ArticleId IdType="pmc">PMC5361596</ArticleId>
            <ArticleId IdType="pubmed">28055301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A.. 
Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442. PMID:29313949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21442</ArticleId>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leskela S, Perez-Mies B, Rosa-Rosa JM, Cristobal E, Biscuola M, Palacios-Berraquero ML. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019;11(7):964. doi:10.3390/cancers11070964. PMID:31324031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11070964</ArticleId>
            <ArticleId IdType="pmc">PMC6678708</ArticleId>
            <ArticleId IdType="pubmed">31324031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32(4):403–413. doi:10.1038/onc.2012.76. PMID:22430211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.76</ArticleId>
            <ArticleId IdType="pubmed">22430211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song J, Chen W, Zhu G, Wang W, Sun F, Zhu J. Immunogenomic profiling and classification of prostate cancer based on HIF-1 signaling pathway. Front Oncol. 2020;10:1374. doi:10.3389/fonc.2020.01374. PMID:32850440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01374</ArticleId>
            <ArticleId IdType="pmc">PMC7425731</ArticleId>
            <ArticleId IdType="pubmed">32850440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi:10.1016/0090-8258(83)90111-7. PMID:6822361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0090-8258(83)90111-7</ArticleId>
            <ArticleId IdType="pubmed">6822361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmenier FM, Lasheen DS, Abouzid K. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur J Med Chem. 2019;183:111718. doi:10.1016/j.ejmech.2019.111718. PMID:31581005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.111718</ArticleId>
            <ArticleId IdType="pubmed">31581005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515–1527. doi:10.1016/j.cellsig.2011.05.004. PMID:21620960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2011.05.004</ArticleId>
            <ArticleId IdType="pubmed">21620960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ. Akt1 and Akt2: differentiating the aktion. Histol Histopathol. 2011;26(5):651–662. doi:10.14670/HH-26.651. PMID:21432781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14670/HH-26.651</ArticleId>
            <ArticleId IdType="pubmed">21432781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, and Mills GB . Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. Plos One. 2010;5(3):e9910. doi:10.1371/journal.pone.0009910. PMID:20361045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0009910</ArticleId>
            <ArticleId IdType="pmc">PMC2845649</ArticleId>
            <ArticleId IdType="pubmed">20361045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vejux A, Guyot S, Montange T, Riedinger JM, Kahn E, Lizard G. Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis. J Nutr Biochem. 2009;20(1):45–61. doi:10.1016/j.jnutbio.2007.12.001. PMID:18495460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jnutbio.2007.12.001</ArticleId>
            <ArticleId IdType="pubmed">18495460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Maira G, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci. 2009;66(20):3363–3373. doi:10.1007/s00018-009-0108-1. PMID:19662498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-009-0108-1</ArticleId>
            <ArticleId IdType="pubmed">19662498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood. 1995;85(3):650–656. doi:10.1182/blood.V85.3.650.bloodjournal853650. PMID:7833468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V85.3.650.bloodjournal853650</ArticleId>
            <ArticleId IdType="pubmed">7833468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget. 2015;6(24):20697–20710. doi:10.18632/oncotarget.4136. PMID:26079538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4136</ArticleId>
            <ArticleId IdType="pmc">PMC4653036</ArticleId>
            <ArticleId IdType="pubmed">26079538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J, Li G, Liu L, Wang Y, Li X, Gong J. AF1q mediates tumor progression in colorectal cancer by regulating AKT signaling. Int J Mol Sci. 2017;18(5):987. doi:10.3390/ijms18050987. PMID:28475127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18050987</ArticleId>
            <ArticleId IdType="pmc">PMC5454900</ArticleId>
            <ArticleId IdType="pubmed">28475127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Man G, Duan A, Liu W, Cheng J, Liu Y, Song J, Zhou H, Shen K. Circular RNA-related CeRNA network and prognostic signature for patients with osteosarcoma. Cancer Manag Res. 2021;13:7527–7541. doi:10.2147/CMAR.S328559. PMID:34629900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S328559</ArticleId>
            <ArticleId IdType="pmc">PMC8494289</ArticleId>
            <ArticleId IdType="pubmed">34629900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter S, Carlson T, Dellacasagrande J, Garcia A, Gibbons S, Hertzog P, Lyons A, Lin L-L, Lynch M, Monie T, et al. TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain. J Immunol. 2009;183(6):3989–3995. doi:10.4049/jimmunol.0901518. PMID:19710467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901518</ArticleId>
            <ArticleId IdType="pubmed">19710467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Liao J, Wang J, Qi M, Wang K, Wu W. TAF1A and ZBTB41 serve as novel key genes in cervical cancer identified by integrated approaches. Cancer Gene Ther. 2021;28(12):1298–1311. doi:10.1038/s41417-020-00278-1. PMID:33311601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41417-020-00278-1</ArticleId>
            <ArticleId IdType="pmc">PMC8636252</ArticleId>
            <ArticleId IdType="pubmed">33311601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaul YD, Yuan B, Thiru P, Nutter-Upham A, McCallum S, Lanzkron C, Bell GW, Sabatini DM. MERAV: a tool for comparing gene expression across human tissues and cell types. Nucleic Acids Res. 2016;44(D1):D560–D566. doi:10.1093/nar/gkv1337. PMID:26626150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkv1337</ArticleId>
            <ArticleId IdType="pmc">PMC4702927</ArticleId>
            <ArticleId IdType="pubmed">26626150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. doi:10.5114/wo.2014.47136. PMID:25691825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId>
            <ArticleId IdType="pmc">PMC4322527</ArticleId>
            <ArticleId IdType="pubmed">25691825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Wang J, Liu J, Zhu L, Ma H, Zou J, Wu W, Wang K. Systematic prediction of key genes for ovarian cancer by co-expression network analysis. J Cell Mol Med. 2020;24(11):6298–6307. doi:10.1111/jcmm.15271. PMID:32319226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.15271</ArticleId>
            <ArticleId IdType="pmc">PMC7294139</ArticleId>
            <ArticleId IdType="pubmed">32319226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–W198. doi:10.1093/nar/gkz369. PMID:31066453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkz369</ArticleId>
            <ArticleId IdType="pmc">PMC6602461</ArticleId>
            <ArticleId IdType="pubmed">31066453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Liao J, Tan C, Zhou H, Wang J, Wang K, Li Y, Wu W. Integrated study of miR-215 promoting breast cancer cell apoptosis by targeting RAD54B. J Cell Mol Med. 2021;25(7):3327–3338. doi:10.1111/jcmm.16402. PMID:33635591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.16402</ArticleId>
            <ArticleId IdType="pmc">PMC8034472</ArticleId>
            <ArticleId IdType="pubmed">33635591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao J, Liu J, Wang J, Wang M. Lnc-CPLC promotes the progression of colorectal cancer via regulating ZBTB34 by competitively binding miR-4319. J Cell Physiol. 2021. doi:10.1002/jcp.30628. PMID:34741317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.30628</ArticleId>
            <ArticleId IdType="pubmed">34741317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32(Web Server issue):W526–W531. doi:10.1093/nar/gkh468. PMID:15215442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkh468</ArticleId>
            <ArticleId IdType="pmc">PMC441606</ArticleId>
            <ArticleId IdType="pubmed">15215442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_6. PMID:28550454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/82_2017_6</ArticleId>
            <ArticleId IdType="pubmed">28550454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorolla MA, Parisi E, Sorolla A. Determinants of sensitivity to radiotherapy in endometrial cancer. Cancers (Basel). 2020;12(7):1906. doi:10.3390/cancers12071906. PMID:32679719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12071906</ArticleId>
            <ArticleId IdType="pmc">PMC7409033</ArticleId>
            <ArticleId IdType="pubmed">32679719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, et al. PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-alpha/VEGF pathway in endometrial cancer. Gynecol Oncol. 2015;138(1):174–180. doi:10.1016/j.ygyno.2015.04.015. PMID:25913131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2015.04.015</ArticleId>
            <ArticleId IdType="pubmed">25913131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019;10:D12160. doi:10.1002/14651858.CD012160.pub2. PMID:31588998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD012160.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6953296</ArticleId>
            <ArticleId IdType="pubmed">31588998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barra F, Evangelisti G, Ferro DL, Di Domenico S, Ferraioli D, Vellone VG, De Cian F, Ferrero S. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019;28(2):131–142. doi:10.1080/13543784.2018.1558202. PMID:30574817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13543784.2018.1558202</ArticleId>
            <ArticleId IdType="pubmed">30574817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majchrzak-Baczmanska D, Malinowski A. Does IGF-1 play a role in the biology of endometrial cancer?
Ginekol Pol. 2016;87(8):598–604. doi:10.5603/GP.2016.0052. PMID:27629137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/GP.2016.0052</ArticleId>
            <ArticleId IdType="pubmed">27629137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwasniewski W, Gozdzicka-Jozefiak A, Wolun-Cholewa M, Polak G, Sierocinska-Sawa J, Kwasniewska A, Kotarski J. Microsatellite polymorphism in the P1 promoter region of the IGF-1 gene is associated with endometrial cancer. Mol Med Rep. 2016;13(6):4950–4958. doi:10.3892/mmr.2016.5181. PMID:27121258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2016.5181</ArticleId>
            <ArticleId IdType="pmc">PMC4878573</ArticleId>
            <ArticleId IdType="pubmed">27121258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Li MX, Wang H, Zeng Z, Li XM. Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pac J Cancer Prev. 2015;16(1):221–225. doi:10.7314/apjcp.2015.16.1.221. PMID:25640355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/apjcp.2015.16.1.221</ArticleId>
            <ArticleId IdType="pubmed">25640355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anisimov VN, Bartke A. The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013;87(3):201–223. doi:10.1016/j.critrevonc.2013.01.005. PMID:23434537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2013.01.005</ArticleId>
            <ArticleId IdType="pmc">PMC4095988</ArticleId>
            <ArticleId IdType="pubmed">23434537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majchrzak-Baczmanska D, Malinowski A, Glowacka E, Wilczynski M. Does IGF-1 play a role in the biology of ovarian cancer?
Ginekol Pol. 2018;89(1):13–19. doi:10.5603/GP.a2018.0003. PMID:29411341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/GP.a2018.0003</ArticleId>
            <ArticleId IdType="pubmed">29411341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min DY, Jung E, Kim J, Lee YH, Shin SY. Leptin stimulates IGF-1 transcription by activating AP-1 in human breast cancer cells. BMB REP. 2019;52(6):385–390. doi:10.5483/BMBRep.2019.52.6.189. PMID:30293548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2019.52.6.189</ArticleId>
            <ArticleId IdType="pmc">PMC6605521</ArticleId>
            <ArticleId IdType="pubmed">30293548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts CJ. IGF-1 and prostate cancer. Novartis Found Symp. 2004;262:193–199, 199–204, 265–268. PMID:15562830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15562830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonning PE, Helle SI. IGF-1 and breast cancer. Novartis Found Symp. 2004;262:205–212, 212–214, 265–268. PMID:15562831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15562831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Wang H, Liu L, Xie A. The role of Insulin/IGF-1/PI3K/Akt/GSK3beta signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73. doi:10.3389/fnins.2018.00073. PMID:29515352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00073</ArticleId>
            <ArticleId IdType="pmc">PMC5826217</ArticleId>
            <ArticleId IdType="pubmed">29515352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmer LT, Hoogaars W, Jaspers RT. The role of IGF-1 signaling in skeletal muscle atrophy. Adv Exp Med Biol. 2018;1088:109–137. doi:10.1007/978-981-13-1435-3_6. PMID:30390250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-981-13-1435-3_6</ArticleId>
            <ArticleId IdType="pubmed">30390250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rong L, Li Z, Leng X, Li H, Ma Y, Chen Y, Song F. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomed Pharmacother. 2020;122:109726. doi:10.1016/j.biopha.2019.109726. PMID:31918283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2019.109726</ArticleId>
            <ArticleId IdType="pubmed">31918283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11(7):1946–1954. doi:10.1039/c5mb00101c. PMID:25924008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c5mb00101c</ArticleId>
            <ArticleId IdType="pubmed">25924008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y, Fan Y, Gao Z, Sun X, Zhang H, Wang Z, Cui Y, Song W, Wang Z, Zhang F, et al. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3beta signaling pathway. Cancer Biol Med. 2020;17(3):707–725. doi:10.20892/j.2095-3941.2020.0056. PMID:32944401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20892/j.2095-3941.2020.0056</ArticleId>
            <ArticleId IdType="pmc">PMC7476086</ArticleId>
            <ArticleId IdType="pubmed">32944401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Zhang H, Liu T, Yang W, Lv W, He D, Guo P, Li L. 6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3beta-cyclin D1 pathway in renal-cell carcinoma. Cancer Chemother Pharmacol. 2020;85(2):379–390. doi:10.1007/s00280-019-03999-9. PMID:31832810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-019-03999-9</ArticleId>
            <ArticleId IdType="pmc">PMC7015962</ArticleId>
            <ArticleId IdType="pubmed">31832810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang E, Sorolla A. Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition. J Gynecol Oncol. 2020;31(3):e29. doi:10.3802/jgo.2020.31.e29. PMID:31912683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3802/jgo.2020.31.e29</ArticleId>
            <ArticleId IdType="pmc">PMC7189072</ArticleId>
            <ArticleId IdType="pubmed">31912683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan B-S, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–1967. doi:10.1158/1535-7163.MCT-09-1012. PMID:20571069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-1012</ArticleId>
            <ArticleId IdType="pubmed">20571069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan N, Park J, Dean WL, Gray RD, Tse W, Lee D, Sabo TM. Recombinant expression and purification of AF1q and its interaction with T-cell Factor 7. Protein Expr Purif. 2020;165:105499. doi:10.1016/j.pep.2019.105499. PMID:31541685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pep.2019.105499</ArticleId>
            <ArticleId IdType="pubmed">31541685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, and Tse W. The oncogene AF1Q is associated with WNT and STAT signaling and offers a novel independent prognostic marker in patients with resectable esophageal cancer. Cells-Basel. 2019;8(11). doi:10.3390/cells8111357. PMID:31671695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8111357</ArticleId>
            <ArticleId IdType="pmc">PMC6912824</ArticleId>
            <ArticleId IdType="pubmed">31671695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia H, Ma H, Li Z, Chen F, Fang B, Cao X, Chang Y, Qiang Z. Downregulation of LncRNA TUG1 inhibited TLR4 signaling pathway-mediated inflammatory damage after spinal cord ischemia reperfusion in rats via suppressing TRIL expression. J Neuropathol ExpNeurol.2019;78(3):268–282.doi:10.1093/jnen/nly126. PMID:30715406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnen/nly126</ArticleId>
            <ArticleId IdType="pubmed">30715406</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35253622</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>211</StartPage>
          <EndPage>224</EndPage>
          <MedlinePgn>211-224</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2046450</ELocationID>
        <Abstract>
          <AbstractText>Endometrial cancer (EC) is a gynecological malignant tumor characterized by high incidence. EC occurrence and development are regulated by numerous molecules and signal pathways. There is a need to explore key regulatory molecules to identify potential therapeutic targets to reduce the incidence of EC. Treatment by targeting a single molecule is characterized by poor efficacy owing to the development of resistance and significant side effects. The current study explored potential candidates in EC by integrating bioinformatics analysis and in vivo and in vitro experimental validation to circumvent the limitation of low efficacy of currently used molecules. Molecular dynamics simulations provide details at the molecular level of intermolecular regulation. In the current study, MLLT11 and TRIL were identified as important regulatory molecules in EC. The two molecules formed a heteromultimer by binding to AKT protein, which induced its phosphorylation of threonine at position 308. Ultimately, the complex stimulates PI3K/AKT/mTOR signaling pathway, a pivotal pathway in tumors. The findings of the current study show a novel complex, MLLT11-TRIL, which can act as AKT protein agonist, thus inducing activity of PI3K/AKT/mTOR signaling pathway. Targeting MLLT11 and TRIL simultaneously, or blocking the formation of the MLLT11-TRIL complex, can abrogate progression of EC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Jingnan</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-0392-6517</Identifier>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-3910-3712</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Mingming</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0186-2721</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jinjin</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-5655-8888</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecology, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mingyuan</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-4867-0508</Identifier>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Geratic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C091736">MLLT11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="Y">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="Y">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AKT</Keyword>
        <Keyword MajorTopicYN="Y">Endometrial cancer (EC)</Keyword>
        <Keyword MajorTopicYN="Y">MLLT11</Keyword>
        <Keyword MajorTopicYN="Y">PI3K/AKT/mTOR signaling pathway</Keyword>
        <Keyword MajorTopicYN="Y">TRIL</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>8</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35253622</ArticleId>
        <ArticleId IdType="pmc">PMC8903758</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2022.2046450</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017;13(3):608–624. doi:10.1080/15548627.2016.1271512. PMID:28055301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1271512</ArticleId>
            <ArticleId IdType="pmc">PMC5361596</ArticleId>
            <ArticleId IdType="pubmed">28055301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A.. 
Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442. PMID:29313949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21442</ArticleId>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leskela S, Perez-Mies B, Rosa-Rosa JM, Cristobal E, Biscuola M, Palacios-Berraquero ML. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019;11(7):964. doi:10.3390/cancers11070964. PMID:31324031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11070964</ArticleId>
            <ArticleId IdType="pmc">PMC6678708</ArticleId>
            <ArticleId IdType="pubmed">31324031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32(4):403–413. doi:10.1038/onc.2012.76. PMID:22430211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.76</ArticleId>
            <ArticleId IdType="pubmed">22430211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song J, Chen W, Zhu G, Wang W, Sun F, Zhu J. Immunogenomic profiling and classification of prostate cancer based on HIF-1 signaling pathway. Front Oncol. 2020;10:1374. doi:10.3389/fonc.2020.01374. PMID:32850440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01374</ArticleId>
            <ArticleId IdType="pmc">PMC7425731</ArticleId>
            <ArticleId IdType="pubmed">32850440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi:10.1016/0090-8258(83)90111-7. PMID:6822361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0090-8258(83)90111-7</ArticleId>
            <ArticleId IdType="pubmed">6822361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmenier FM, Lasheen DS, Abouzid K. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur J Med Chem. 2019;183:111718. doi:10.1016/j.ejmech.2019.111718. PMID:31581005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.111718</ArticleId>
            <ArticleId IdType="pubmed">31581005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515–1527. doi:10.1016/j.cellsig.2011.05.004. PMID:21620960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2011.05.004</ArticleId>
            <ArticleId IdType="pubmed">21620960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ. Akt1 and Akt2: differentiating the aktion. Histol Histopathol. 2011;26(5):651–662. doi:10.14670/HH-26.651. PMID:21432781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14670/HH-26.651</ArticleId>
            <ArticleId IdType="pubmed">21432781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, and Mills GB . Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. Plos One. 2010;5(3):e9910. doi:10.1371/journal.pone.0009910. PMID:20361045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0009910</ArticleId>
            <ArticleId IdType="pmc">PMC2845649</ArticleId>
            <ArticleId IdType="pubmed">20361045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vejux A, Guyot S, Montange T, Riedinger JM, Kahn E, Lizard G. Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis. J Nutr Biochem. 2009;20(1):45–61. doi:10.1016/j.jnutbio.2007.12.001. PMID:18495460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jnutbio.2007.12.001</ArticleId>
            <ArticleId IdType="pubmed">18495460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Maira G, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci. 2009;66(20):3363–3373. doi:10.1007/s00018-009-0108-1. PMID:19662498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-009-0108-1</ArticleId>
            <ArticleId IdType="pubmed">19662498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood. 1995;85(3):650–656. doi:10.1182/blood.V85.3.650.bloodjournal853650. PMID:7833468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V85.3.650.bloodjournal853650</ArticleId>
            <ArticleId IdType="pubmed">7833468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget. 2015;6(24):20697–20710. doi:10.18632/oncotarget.4136. PMID:26079538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4136</ArticleId>
            <ArticleId IdType="pmc">PMC4653036</ArticleId>
            <ArticleId IdType="pubmed">26079538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J, Li G, Liu L, Wang Y, Li X, Gong J. AF1q mediates tumor progression in colorectal cancer by regulating AKT signaling. Int J Mol Sci. 2017;18(5):987. doi:10.3390/ijms18050987. PMID:28475127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18050987</ArticleId>
            <ArticleId IdType="pmc">PMC5454900</ArticleId>
            <ArticleId IdType="pubmed">28475127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Man G, Duan A, Liu W, Cheng J, Liu Y, Song J, Zhou H, Shen K. Circular RNA-related CeRNA network and prognostic signature for patients with osteosarcoma. Cancer Manag Res. 2021;13:7527–7541. doi:10.2147/CMAR.S328559. PMID:34629900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S328559</ArticleId>
            <ArticleId IdType="pmc">PMC8494289</ArticleId>
            <ArticleId IdType="pubmed">34629900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter S, Carlson T, Dellacasagrande J, Garcia A, Gibbons S, Hertzog P, Lyons A, Lin L-L, Lynch M, Monie T, et al. TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain. J Immunol. 2009;183(6):3989–3995. doi:10.4049/jimmunol.0901518. PMID:19710467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901518</ArticleId>
            <ArticleId IdType="pubmed">19710467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Liao J, Wang J, Qi M, Wang K, Wu W. TAF1A and ZBTB41 serve as novel key genes in cervical cancer identified by integrated approaches. Cancer Gene Ther. 2021;28(12):1298–1311. doi:10.1038/s41417-020-00278-1. PMID:33311601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41417-020-00278-1</ArticleId>
            <ArticleId IdType="pmc">PMC8636252</ArticleId>
            <ArticleId IdType="pubmed">33311601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaul YD, Yuan B, Thiru P, Nutter-Upham A, McCallum S, Lanzkron C, Bell GW, Sabatini DM. MERAV: a tool for comparing gene expression across human tissues and cell types. Nucleic Acids Res. 2016;44(D1):D560–D566. doi:10.1093/nar/gkv1337. PMID:26626150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkv1337</ArticleId>
            <ArticleId IdType="pmc">PMC4702927</ArticleId>
            <ArticleId IdType="pubmed">26626150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. doi:10.5114/wo.2014.47136. PMID:25691825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2014.47136</ArticleId>
            <ArticleId IdType="pmc">PMC4322527</ArticleId>
            <ArticleId IdType="pubmed">25691825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Wang J, Liu J, Zhu L, Ma H, Zou J, Wu W, Wang K. Systematic prediction of key genes for ovarian cancer by co-expression network analysis. J Cell Mol Med. 2020;24(11):6298–6307. doi:10.1111/jcmm.15271. PMID:32319226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.15271</ArticleId>
            <ArticleId IdType="pmc">PMC7294139</ArticleId>
            <ArticleId IdType="pubmed">32319226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–W198. doi:10.1093/nar/gkz369. PMID:31066453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkz369</ArticleId>
            <ArticleId IdType="pmc">PMC6602461</ArticleId>
            <ArticleId IdType="pubmed">31066453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Liao J, Tan C, Zhou H, Wang J, Wang K, Li Y, Wu W. Integrated study of miR-215 promoting breast cancer cell apoptosis by targeting RAD54B. J Cell Mol Med. 2021;25(7):3327–3338. doi:10.1111/jcmm.16402. PMID:33635591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.16402</ArticleId>
            <ArticleId IdType="pmc">PMC8034472</ArticleId>
            <ArticleId IdType="pubmed">33635591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao J, Liu J, Wang J, Wang M. Lnc-CPLC promotes the progression of colorectal cancer via regulating ZBTB34 by competitively binding miR-4319. J Cell Physiol. 2021. doi:10.1002/jcp.30628. PMID:34741317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.30628</ArticleId>
            <ArticleId IdType="pubmed">34741317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32(Web Server issue):W526–W531. doi:10.1093/nar/gkh468. PMID:15215442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkh468</ArticleId>
            <ArticleId IdType="pmc">PMC441606</ArticleId>
            <ArticleId IdType="pubmed">15215442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_6. PMID:28550454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/82_2017_6</ArticleId>
            <ArticleId IdType="pubmed">28550454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorolla MA, Parisi E, Sorolla A. Determinants of sensitivity to radiotherapy in endometrial cancer. Cancers (Basel). 2020;12(7):1906. doi:10.3390/cancers12071906. PMID:32679719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12071906</ArticleId>
            <ArticleId IdType="pmc">PMC7409033</ArticleId>
            <ArticleId IdType="pubmed">32679719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, et al. PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-alpha/VEGF pathway in endometrial cancer. Gynecol Oncol. 2015;138(1):174–180. doi:10.1016/j.ygyno.2015.04.015. PMID:25913131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2015.04.015</ArticleId>
            <ArticleId IdType="pubmed">25913131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019;10:D12160. doi:10.1002/14651858.CD012160.pub2. PMID:31588998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD012160.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6953296</ArticleId>
            <ArticleId IdType="pubmed">31588998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barra F, Evangelisti G, Ferro DL, Di Domenico S, Ferraioli D, Vellone VG, De Cian F, Ferrero S. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019;28(2):131–142. doi:10.1080/13543784.2018.1558202. PMID:30574817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13543784.2018.1558202</ArticleId>
            <ArticleId IdType="pubmed">30574817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majchrzak-Baczmanska D, Malinowski A. Does IGF-1 play a role in the biology of endometrial cancer?
Ginekol Pol. 2016;87(8):598–604. doi:10.5603/GP.2016.0052. PMID:27629137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/GP.2016.0052</ArticleId>
            <ArticleId IdType="pubmed">27629137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwasniewski W, Gozdzicka-Jozefiak A, Wolun-Cholewa M, Polak G, Sierocinska-Sawa J, Kwasniewska A, Kotarski J. Microsatellite polymorphism in the P1 promoter region of the IGF-1 gene is associated with endometrial cancer. Mol Med Rep. 2016;13(6):4950–4958. doi:10.3892/mmr.2016.5181. PMID:27121258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2016.5181</ArticleId>
            <ArticleId IdType="pmc">PMC4878573</ArticleId>
            <ArticleId IdType="pubmed">27121258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Li MX, Wang H, Zeng Z, Li XM. Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pac J Cancer Prev. 2015;16(1):221–225. doi:10.7314/apjcp.2015.16.1.221. PMID:25640355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/apjcp.2015.16.1.221</ArticleId>
            <ArticleId IdType="pubmed">25640355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anisimov VN, Bartke A. The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013;87(3):201–223. doi:10.1016/j.critrevonc.2013.01.005. PMID:23434537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2013.01.005</ArticleId>
            <ArticleId IdType="pmc">PMC4095988</ArticleId>
            <ArticleId IdType="pubmed">23434537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majchrzak-Baczmanska D, Malinowski A, Glowacka E, Wilczynski M. Does IGF-1 play a role in the biology of ovarian cancer?
Ginekol Pol. 2018;89(1):13–19. doi:10.5603/GP.a2018.0003. PMID:29411341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/GP.a2018.0003</ArticleId>
            <ArticleId IdType="pubmed">29411341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min DY, Jung E, Kim J, Lee YH, Shin SY. Leptin stimulates IGF-1 transcription by activating AP-1 in human breast cancer cells. BMB REP. 2019;52(6):385–390. doi:10.5483/BMBRep.2019.52.6.189. PMID:30293548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2019.52.6.189</ArticleId>
            <ArticleId IdType="pmc">PMC6605521</ArticleId>
            <ArticleId IdType="pubmed">30293548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts CJ. IGF-1 and prostate cancer. Novartis Found Symp. 2004;262:193–199, 199–204, 265–268. PMID:15562830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15562830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonning PE, Helle SI. IGF-1 and breast cancer. Novartis Found Symp. 2004;262:205–212, 212–214, 265–268. PMID:15562831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15562831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Wang H, Liu L, Xie A. The role of Insulin/IGF-1/PI3K/Akt/GSK3beta signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73. doi:10.3389/fnins.2018.00073. PMID:29515352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00073</ArticleId>
            <ArticleId IdType="pmc">PMC5826217</ArticleId>
            <ArticleId IdType="pubmed">29515352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmer LT, Hoogaars W, Jaspers RT. The role of IGF-1 signaling in skeletal muscle atrophy. Adv Exp Med Biol. 2018;1088:109–137. doi:10.1007/978-981-13-1435-3_6. PMID:30390250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-981-13-1435-3_6</ArticleId>
            <ArticleId IdType="pubmed">30390250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rong L, Li Z, Leng X, Li H, Ma Y, Chen Y, Song F. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomed Pharmacother. 2020;122:109726. doi:10.1016/j.biopha.2019.109726. PMID:31918283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2019.109726</ArticleId>
            <ArticleId IdType="pubmed">31918283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11(7):1946–1954. doi:10.1039/c5mb00101c. PMID:25924008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c5mb00101c</ArticleId>
            <ArticleId IdType="pubmed">25924008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y, Fan Y, Gao Z, Sun X, Zhang H, Wang Z, Cui Y, Song W, Wang Z, Zhang F, et al. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3beta signaling pathway. Cancer Biol Med. 2020;17(3):707–725. doi:10.20892/j.2095-3941.2020.0056. PMID:32944401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20892/j.2095-3941.2020.0056</ArticleId>
            <ArticleId IdType="pmc">PMC7476086</ArticleId>
            <ArticleId IdType="pubmed">32944401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Zhang H, Liu T, Yang W, Lv W, He D, Guo P, Li L. 6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3beta-cyclin D1 pathway in renal-cell carcinoma. Cancer Chemother Pharmacol. 2020;85(2):379–390. doi:10.1007/s00280-019-03999-9. PMID:31832810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-019-03999-9</ArticleId>
            <ArticleId IdType="pmc">PMC7015962</ArticleId>
            <ArticleId IdType="pubmed">31832810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang E, Sorolla A. Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition. J Gynecol Oncol. 2020;31(3):e29. doi:10.3802/jgo.2020.31.e29. PMID:31912683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3802/jgo.2020.31.e29</ArticleId>
            <ArticleId IdType="pmc">PMC7189072</ArticleId>
            <ArticleId IdType="pubmed">31912683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan B-S, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–1967. doi:10.1158/1535-7163.MCT-09-1012. PMID:20571069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-1012</ArticleId>
            <ArticleId IdType="pubmed">20571069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan N, Park J, Dean WL, Gray RD, Tse W, Lee D, Sabo TM. Recombinant expression and purification of AF1q and its interaction with T-cell Factor 7. Protein Expr Purif. 2020;165:105499. doi:10.1016/j.pep.2019.105499. PMID:31541685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pep.2019.105499</ArticleId>
            <ArticleId IdType="pubmed">31541685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, and Tse W. The oncogene AF1Q is associated with WNT and STAT signaling and offers a novel independent prognostic marker in patients with resectable esophageal cancer. Cells-Basel. 2019;8(11). doi:10.3390/cells8111357. PMID:31671695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8111357</ArticleId>
            <ArticleId IdType="pmc">PMC6912824</ArticleId>
            <ArticleId IdType="pubmed">31671695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia H, Ma H, Li Z, Chen F, Fang B, Cao X, Chang Y, Qiang Z. Downregulation of LncRNA TUG1 inhibited TLR4 signaling pathway-mediated inflammatory damage after spinal cord ischemia reperfusion in rats via suppressing TRIL expression. J Neuropathol ExpNeurol.2019;78(3):268–282.doi:10.1093/jnen/nly126. PMID:30715406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnen/nly126</ArticleId>
            <ArticleId IdType="pubmed">30715406</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
